For immunotherapy, monoclonal antibodies/bispecific T-cell engaging antibodies, anti-PD1/PDL1 checkpoint inhibitors, and CAR-T for T-ALL therapy are summarized. Here, CD274 is linked to acute lymphoblastic leukemia.